Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 397-409

  Vernon, Anthony C ^a   Zbarsky, Virginia ^a   Datla, Krishna P ^a   Dexter, David T ^a   Croucher, Martin J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 PHOSPHONOBUTYRIC ACID; ALPHA METHYLSERINE O PHOSPHATE; METABOTROPIC RECEPTOR 3; OXIDOPAMINE;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IN VIVO STUDY; MALE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; AMINOBUTYRIC ACIDS; ANIMALS; CORPUS STRIATUM; GAMMA-AMINOBUTYRIC ACID; HOMOVANILLIC ACID; MALE; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PHOSPHOSERINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SUBSTANTIA NIGRA;

EID: 33845876394     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.108159     Document Type: Article

References (41)

1. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Traficante A, Nicoletti F, Bruno V (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci 26:7222-7229.
2. Blandini F, Nappi G, and Greenamyre JT (2001) Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann Neurol 49:525-529.
3. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, and Nicoletti F (1998) Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 18:9594-9600.
4. Bruno V, Battaglia G, Ksiazek I, van der Putten H, Catania MV, Giuffrida R, Lukic S, Leonhardt T, Inderbitzin W, Gasparini F, et al. (2000) Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J Neurosci 20:6413-6420.
5. Cai Z, Saugstad JA, Sorensen SD, Ciombor KJ, Zhang C, Schaffhauser H, Hubalek F, Pohl J, Duvoisin RM, and Conn PJ (2001) Cyclic AMP-dependent protein kinase phosphorylates group III metabotropic glutamate receptors and inhibits their function as presynaptic receptors. J Neurochem 78:756-766.
6. Carman LS, Gage FH, and Shults CW (1991) Partial lesion of the substantia nigra: relation between extent of lesion and rotational behaviour. Brain Res 553:275-283.
7. Cartmell J and Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75:889-907.
8. Conn PJ (2003) Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann NY Acad Sci 1003:12-21.
9. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
10. Giustizieri M, Bernardi G, Mercuri NB, and Berretta N (2005) Distinct mechanisms of presynaptic inhibition at GABAergic synapses of the rat substantia nigra pars compacta. J Neurophysiol 94:1992-2003.
11. Iribe Y, Moore K, Pang KC, and Tepper JM (1999) Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurons in vitro. J Neurophysiol 82:925-933.
12. Jenner P and Olanow CW (1998) Understanding cell death in Parkinson's disease. Ann Neurol 44:S72-S84.
13. Jiang Q, Yan Z, and Feng J (2006) Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on dopaminergic neurons through a microtubule-dependent mechanism. J Neurosci 26:4318-4328.
14. Katayama J, Akaike N, and Nabekura J (2003) Characterization of pre- and postsynaptic metabotropic glutamate receptor-mediated inhibitory responses in substantia nigra dopamine neurons. Neurosci Res 45:101-115.
15. Kosinski CM, Risso Bradley S, Conn PJ, Levey AI, Landwehrmeyer GB, Penney JB Jr, Young AB, and Standaert DG (1999) Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. J Comp Neurol 415:266-284.
16. Lafon-Cazal M, Fagni L, Guiraud MJ, Mary S, Lerner-Natoli M, Pin JP, Shigemoto R, and Bockaert J (1999a) mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons. Eur J Neurosci 11:663-672.
17. B receptor activation enhance neurotoxic effects of N-methyl-D-aspartate in cultured mouse striatal GABAergic neurones. Neuropharmacology 38:1631-1640.
18. Lang AE and Lozano AM (1998a) Parkinson's disease: first of two parts. N Engl J Med 339:1044-1053.
19. Lee JM, Zipfel GJ, and Choi DW (1999) The changing landscape of ischaemic brain injury mechanisms. Nature (Lond) 399:A7-A14.
20. MacInnes M, Messenger MJ, and Duty S (2004) Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br J Pharmacol 141:15-22.
21. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, et al. (2003) (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 45:895-906.
22. Mundell SJ, Pula G, More JC, Jane DE, Roberts PJ, and Kelly E (2004) Activation of cyclic AMP-dependent protein kinase inhibits the desensitization and internalization of metabotropic glutamate receptors 1a and 1b. Mol Pharmacol 65:1507-1516.
23. Murray TK, Messenger MJ, Ward MA, Woodhouse S, Osbourne DJ, Duty S, and O'Niell MJ (2002) Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav 73:455-466.
24. Nicoletti F, Bruno V, Copani A, Casabona G, and Knopfel T (1996) Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci 19:267-271.
25. Olanow CW and Jankovic J (2005) Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 20:S3-S10.
26. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates, 2nd ed, Academic Press, Inc. (London) Ltd., London, UK.
27. Rodriguez MC, Obeso JA, and Olanow CW (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44:S175-188.
28. Schapira AH (2005) Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry 76:1472-1478.
29. Schoepp DD, Jane DE, and Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431-1476.
30. Smith Y, Hazrati LN, and Parent A (1990) Efferent projections of the subthalamic nucleus in the squirrel monkey as studied by the PHA-L anterograde tracing method. J Comp Neurol 294:306-323.
31. Sonsalla PK, Albers DS, and Zeevalk GD (1998) Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids 14:69-74.
32. Stanic D, Finkelstein DI, Bourke DW, Drago J, and Horne MK (2003) Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur J Neurosci 18:1175-1188.
33. Taylor DL, Diemel LT, and Pocock JM (2003) Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J Neurosci 23:2150-2160.
34. Turski L, Bressler K, Rettig KJ, Loschmann PA, and Wachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl- D-aspartate antagonists. Nature (Lond) 349:414-418.
35. Valenti O, Mannaioni G, Seabrook GR, Conn PJ, and Marino MJ (2005) Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J Pharmacol Exp Ther 313:1296-1304.
36. Vernon AC, Palmer S, Datla KP, Zbarsky V, Croucher MJ, and Dexter DT (2005) Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur J Neurosci 22:1799-1806.
37. Wigmore MA and Lacey MG (1998) Metabotropic glutamate receptors depress glutamate-mediated synaptic input to rat midbrain dopamine neurones in vitro. Br J Pharmacol 123:667-674.
38. Wittmann M, Marino MJ, Bradley SR, and Conn PJ (2001) Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata. J Neurophysiol 85:1960-1968.
39. Wittmann M, Marino MJ, and Conn PJ (2002) Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata. J Pharmacol Exp Ther 302:433-441.
40. Yao HH, Ding JH, Zhou F, Wang F, Hu L-F, Sun T, and Hu G (2005) Enhancement of glutamate uptake mediates the neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes. J. Neurochem 92:948-961.
41. Yuan H, Sarre S, Ebinger G, and Michotte Y (2005) Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 144:35-45.